FDA DEVICE FACTS
FilmArray Pneumonia Panel plus
Biofire Diagnostics, LLC
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The BIOFIRE ® FILMARRAY® Pneumonia Panel plus (BIOFIRE Pneumonia Panel plus) is a multiplexed nucleic acid test intended for use with BIOFIRE® FILMARRAY® 2.0 (BIOFIRE 2.0) or BIOFIRE® FILMARRAY® TORCH (BIOFIRE TORCH) systems for the simultaneous detection and identification of nucleic acids from Middle East respiratory syndrome coronavirus (MERS - CoV) and multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum -like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL) -like specimens (BAL or mi ni-BAL) obtained from individuals meeting MERS-CoV clinical and/or epidemiological criteria. Testing with BIOFIRE Pneumonia Panel plus should not be performed unless the patient meets clinical and/or epidemiologic criteria for testing suspected MERS-CoV specimens. This includes: clinical signs and symptoms associated with MERS -CoV infection, contact with a probable or confirmed MERS-CoV case, history of travel to geographic locations where MERS -CoV cases were detected, or other epidemiological links for which MERS-CoV testing may be indicated. The following bacteria are reported semi-quantitatively with bins representing approximately 10^4, 10^5, 10^6, or ≥10^7 genomic copies of bacterial nucleic acid per milliliter (copies/mL) of specimen, to a id in estimating relative abundance of nucleic acid from these common bacteria within a specimen: Bacteria reported with bins of 10^4, 10^5, 10^6, or ≥10^7 copies/mL Acinetobacter calcoaceticus-baumannii complex Klebsiella oxytoca Serratia marcescens Enterobacter cloacae complex Klebsiella pneumoniae group Staphylococcus aureus Escherichia coli Moraxella catarrhalis Streptococcus agalactiae Haemophilus influenzae Proteus spp. Streptococcus pneumoniae Klebsiella aerogenes Pseudomonas aeruginosa Streptococcus pyogenes The following atypical bacteria, viruses, and antimicrobial resistance genes are reported qualitatively: Atypical Bacteria Chlamydia pneumoniae Legionella pneumophila Mycoplasma pneumoniae Viruses Middle East respiratory syndrome coronavirus (MERS-CoV) Adenovirus Human rhinovirus/enterovirus Parainfluenza virus Coronavirus Influenza A virus Respiratory syncytial virus Human metapneumovirus Influenza B virus Antimicrobial Resistance Genes CTX-M NDM mecA/C and MREJ (MRSA) IMP OXA-48-like KPC VIM The detection and identification of specific viral and bacterial nucleic acids from MERS-CoV and other respiratory pathogens, as well as the estimation of relative abundance of nucleic acid from common bacterial analytes, within specimens collected from individuals meeting MERS -CoV clinical and/or epidemiological criteria aids in the differential diagnosis of MERS-CoV infection, if used in conjunction with other clinical and epidemiological information in accordance with the guidelines provided by the appropriate public health authorities. BIOFIRE Pneumonia Panel plus MERS-CoV positive results are for the presumptive identification of MERS -CoV. The definitive identification of MERS -CoV requires additional testing and confirmation procedures in consultation with the appropriate public health authorities (e.g., local or state public health departments, etc.) for whom reporting is necessary. The diagnosis of MERS- CoV infection must be made based on history, signs, symptoms, exposure likelihood, and other laboratory evidence in addition to the identification of MERS-CoV. BIOFIRE Pneumonia Panel plus MERS-CoV negative results, even in the context of a BIOFIRE Pneumonia Panel plus positive result for one or more of the common respiratory pathogens, do not preclude MERS -CoV infection and should not be used as the sole basis for patient management decisions. The levels of MERS -CoV that would be present in sputum -like or BAL-like specimens from individuals with early infection and from asymptomatic MERS -CoV carriers are not well understood. A negative BIOFIRE Pneumonia Panel plus MERS-CoV result in an asymptomatic individual does not rule out the possibility of future illness and does not demonstrate that the individual is not infectious. Viral culture should not be attempted on specimens with positive BIOFIRE Pneumonia Panel plus results for MERS-CoV unless a BSL 3 facility is available to receive and culture specimens. Negative results in the setting of a respiratory illness may be due to infection with pathogens that are not detected by this test, pathogens below the limit of detection, or in the case of bacterial analytes, present at levels below the lowest reported 10 ^4 copies/mL bin. Detection of analytes does not rule out co -infection with other organisms; the agent(s) detected by the BIOFIRE Pneumonia Panel plus may not be the definite cause of disease. Additional laboratory testing (e.g. bacterial and viral culture, immunofluorescence, and radiography) may be necessary when evaluating a patient with possible lower respiratory tract infection.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。